November II, 2023

New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.

In the phase 3 MURANO trial, there was a continued survival benefit in patients with chronic lymphocytic leukemia treated with fixed-duration venetoclax plus rituximab.

Among patients with chronic lymphocytic leukemia who progressed after treatment, pirtobrutinib demonstrated a clearance of BTK C481 clones and the development of non-C481 clones.

Findings from the EPCORE CLL-1 trial were presented by Arnon Kater, MD, PhD, during the 2023 International Workshop on CLL, held October 6 to 9, 2023, in Boston, Massachusetts.

AMG 193 had a promising safety profile and robust target engagement in a dose-escalating trial across tumor types.

RMC-6236 was safe and tolerable in patients with mutant solid tumors harboring KRAS G12X mutations across various cancer types.

In this article, John M. Burke, MD, discusses the high prices of prescription drugs and the new law that allows the government to negotiate drug prices with manufacturers.

At the recent European Society for Medical Oncology Congress 2023, a number of trials evaluated antibody-drug conjugates in non–small cell lung cancer.